PEER-REVIEW | INJECTABLE TREATMENTS | Figure 4 Reported bruising at insertion point
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
97% 80% 55%
Figure 5 Reported swelling at insertion point 93%
25% 17% 3% None Mild Moderate Severe BRUISING Bruising
All patients continued to use medically-prescribed blood thinners and were not told to stop taking anti-inflammatories, supplements such as vitamin C and Omegas, or any other blood-thinning agents. Not a single patient reported bruising
Not a single patient reported
bruising at the treated anatomical areas, but bruising was noted at the insertion point.
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
74 ❚ 88%
at the treated anatomical areas, but bruising was noted at the insertion point. The same grading system used for erythema was also used for reporting bruising at the insertion point (Figure 4). A total of 55% of patients had no bruising at the insertion point, while 25% reported mild bruising, 17% reported moderate bruising, and 3% reported severe bruising (could not be hidden with make-up).
This
indicates that for the majority of patients (93%), they would not need to postpone or interrupt any social events as a result of visible bruising at either the treated area or the entry point following a treatment with a microcannula.
Figure 6 Reported tenderness at insertion point None to mild None to moderate
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
65% 100%
28% 7% 0% None Mild Moderate Severe SWELLING
Swelling In all, 65% of patients reported no visible swelling, while 35% of patients reported mild to moderate swelling (Figure 5). No patients reported severe swelling, which again indicates that swelling following microcannula treatment will be unlikely to affect social events.
Tenderness at insertion site A total of 58% of patients reported no pain or discomfort at the microcannula entry point owing to the lidocaine/adrenaline bolus
injection (Figure 6) and 30%
reported a pain rating between 1 and 3. Only 12% of patients rated the pain at the entry point post procedure between 4 and 10. This indicates that for the majority of patients (88%), very little to no pain will be experienced when injecting the local anaesthetic at the
entry point. However, it also indicates the variability of pain tolerance (or perceived discomfort) for a fairly large number of the general population (12%).
Figure 7 Reported tenderness at treated area 58% 42% 30% 25% 10% 2% No Yes 0 to 3 1 to 3 2 to 3 4 to 6 TENDERNESS AT SITE OF INSERTION POINT 7 to 10 4 to 10 12%
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
85% 62% 38% 21% 12% No Yes 0 to 3 1 to 3 2 to 3 15% 0% 4 to 6 TENDERNESS OF THE TREATED AREA(S) 7 to 10 4 to 10 15% None to mild None to moderate
October 2013 |
prime-journal.com
Patient %
Patient %
Patient %
Patient %
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100